Patent: 9,931,402
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 9,931,402
Title: | Compositions for the treatment of solid tumors |
Abstract: | The present invention relates to a pharmaceutical combination that comprises an IGF1R inhibitor and an mTOR inhibitor for the treatment of cancer in a subject; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of medicament for the treatment of cancer; a kit comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and a method of treating cancer in a subject, especially a human. |
Inventor(s): | Hurwitz; Herbert I. (Durham, NC), Vlahovic; Gordana (Durham, NC) |
Assignee: | Duke University (Durham, NC) |
Application Number: | 15/586,727 |
Patent Claims: | see list of patent claims |
Details for Patent 9,931,402
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | ZOSTAVAX | zoster vaccine live | For Injection | 125123 | 05/25/2006 | See Plans and Pricing | 2031-11-11 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |